MabCure Launches Clinical Trial to Diagnose Ovarian Cancer
January 06 2010 - 9:30AM
Business Wire
MabCure, N.V. (“MabCure”) a wholly-owned subsidiary of MabCure
Inc. (OTCBB: MBCI) , a biotech company that has developed a series
of highly specific monoclonal antibodies (MAbs) to combat various
types of cancers, has signed a clinical research agreement with the
Ramathibodi Hospital, Mahidol University in Bangkok, Thailand. The
study aims to evaluate MabCure’s panel of anti-ovarian MAbs in
diagnosing the presence of ovarian cancer in patients suspected of
having the disease.
Dr. Amnon Gonenne, MabCure’s President and CEO commented, “We
are very excited about the commencement of this study. We have been
working hard to establish key partnerships with respectable
research institutions and hospitals in Europe and the Far East, and
this is no exception. We are looking forward to the results of the
study and to moving MabCure forward towards having our diagnostic
products on the market.”
“We know our diagnostic products have the potential to save many
lives, and our mission is to get them to market as quickly as
possible,” Dr. Gonenne added.
Ovarian cancer is the most lethal of all gynecological cancers.
According to estimates by the American Cancer Society (ACS), in
2009 alone 21,550 American women will have been diagnosed with
ovarian cancer, and 14,600 American women are expected to die of
this disease. The high mortality is mostly attributable to late
diagnosis of the disease. According to the ACS, early detection of
ovarian cancer, when the disease is still localized, can yield a
five-year survival rate of 92% compared to 23% when the disease has
already metastasized.
Recent advances in proteomics-based tests, which rely on
measuring the relative abundance of normal proteins, help in
estimating the likelihood of having ovarian cancer. However, by
definition, these tests cannot provide a definitive diagnosis since
they rely on statistical estimates and not on cancer-specific
biomarkers. Furthermore, a new study by the National Cancer
Institute [J. Natl Cancer Inst. 2010, 102:1-3, 26-38] reports that
the use of such normal proteins for diagnosis of ovarian cancer may
have limited practical usefulness for early intervention, since
these proteins become substantially elevated only in the last year
before clinical diagnosis. It is important to note that over 80% of
ovarian cancer patients are clinically diagnosed with highly
advanced disease (stages III and IV). Therefore, there is clearly
an urgent need for the development of a definitive method for the
early detection of ovarian cancer which relies on cancer-specific
markers. The objective of MabCure’s clinical studies is to apply
its highly specific antibodies for the definitive diagnosis of
ovarian cancer with the ultimate goal of early diagnosis when the
disease is highly curable.
“MabCure’s proprietary platform technology has allowed us to
develop a number of cancer-specific MAbs that could be invaluable
for the diagnosis of several types of lethal cancers, and we are
looking forward to exploring their utility in the clinical setting
as well,” said Dr. Gonenne.
About MabCure
MabCure is a biotechnology company whose vision is to change the
perception of cancer as being a largely incurable disease. MabCure
owns proprietary technology for the creation of unique and highly
specific monoclonal antibodies (MAbs) which will be developed as
diagnostic tools, imaging agents and drugs to treat lethal cancers.
MabCure’s initial goal is to develop its novel MAbs as diagnostic
tools for the detection of ovarian and prostate cancers at an early
stage, when these diseases are still localized and highly curable.
For further information visit MabCure’s website at
http://www.mabcure.com.
About Mahidol University and Ramathibodi Hospital, Bangkok,
Thailand
Mahidol University is one of the oldest and most prestigious
universities in Thailand. It is internationally known and
recognized for the high caliber of research and teaching by its
faculty, as well as its outstanding achievements in international
academic collaboration and professional services. Mahidol
University encompasses three teaching hospitals and one medical
center which produces 1,000 physicians annually and serves as a
center for comprehensive specialist medical training and patient
care, with 4,000 beds serving nearly 4 million outpatients and
140,000 in-patients per year.
Ramathibodi Hospital provides more than 1,000 beds for the care
of complicated and severely ill patients in various departments and
serves 5,000 out-patients per day. The hospital’s faculty is
involved with clinical research in a variety of fields, including
bone marrow transplantation projects, stem cells, advanced
diagnostics and imaging.
Information provided in this press release may contain
statements relating to current expectations, estimates, forecasts
and projections about future events that are "forward-looking
statements" as defined in the Private Securities Litigation Reform
Act of 1995. These forward-looking statements generally relate to
Mabcure’s plans, objectives and expectations for future operations
and are based upon its management's current estimates and
projections of future results or trends. Actual future results may
differ materially from those projected as a result of certain risks
and uncertainties. For a discussion of such risks and
uncertainties, see "Risk Factors" as described in Mabcure’s filings
with the Securities and Exchange Commission.
MabCure (CE) (USOTC:MBCI)
Historical Stock Chart
From Jun 2024 to Jul 2024
MabCure (CE) (USOTC:MBCI)
Historical Stock Chart
From Jul 2023 to Jul 2024
